ED
Editas Medicine, Inc.
EDIT · NASDAQ
$2.90 +2.11% (+$0.06)
1M +5.84%
Market Cap $445.0M
P/E Ratio -
Div. Yield -
ROE 196.63%
Bulios Fair Price
$1.74
40.0% downside
Current Price
$2.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EDIT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
24 /100
Expensive P/B 4.23x
P/S 9.47x
EV/FFO N/A
Growth
78 /100
Growing Book val. growth 57.71%
Rev. growth 27.15%
FCF growth N/A
Profitability
20 /100
Weak Net margin 157.32%
Op. margin 174.71%
FCF margin 256.46%
Quality
3 /100
Poor ROE 196.63%
ROA 31.15%
Asset turnover 0.20x
Debt
100 /100
Low Current ratio 3.19x
Int. coverage 34.55x
Debt/Equity 0.15x
Stability
13 /100
Unstable Rev. volatility 185.50%
EPS volatility 46.11%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EDIT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gilmore O'Neill
Employees
87
Headquarters
Cambridge
Upcoming events
09 NOV
Earnings
Upcoming earnings report